Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-09 00:08 | 2026-01-07 | ANAB | AnaptysBio Inc. | MULROY DENNIS | Officer | OPT+S | $45.11 | 1,908 | $86,070 | 17,667 |
| 2026-01-09 00:12 | 2026-01-07 | ANAB | AnaptysBio Inc. | LOUMEAU ERIC J | Officer | OPT+S | $45.56 | 9,639 | $439,200 | 9,157 |
| 2026-01-09 00:05 | 2026-01-06 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | FRATES JAMES M | Officer | SELL | $11.11 | 3,326 | $36,954 | 177,104 |
| 2026-01-09 00:04 | 2026-01-06 | VRTX | VERTEX PHARMACEUTICALS INC / MA | WAGNER CHARLES F JR | Officer | OPT+S | $461.00 | 9,532 | $4,394,252 | 37,725 |
| 2026-01-09 00:57 | 2025-12-31 | ZNTL | Zentalis Pharmaceuticals, Inc. | WALTERS GROUP | 10% owner | BUY | $1.20 | 6,459,973 | $7,751,968 | 13,509,973 |
| 2026-01-09 01:19 | 2026-01-06 | INSM | INSMED Inc | Smith Michael Alexander | Officer | SELL | $174.00 | 3,158 | $549,494 | 57,037 |
| 2026-01-09 01:20 | 2026-01-06 | INSM | INSMED Inc | Flammer Martina M.D. | Officer | OPT+S | $174.06 | 16,530 | $2,877,139 | 86,794 |
| 2026-01-09 01:22 | 2026-01-06 | INSM | INSMED Inc | Adsett Roger | Officer | SELL | $174.06 | 4,290 | $746,711 | 107,601 |
| 2026-01-09 01:21 | 2026-01-06 | INSM | INSMED Inc | Bonstein Sara | Officer | SELL | $174.22 | 4,642 | $808,733 | 80,506 |
| 2026-01-09 01:20 | 2026-01-06 | INSM | INSMED Inc | Lewis William | Director, Officer | SELL | $174.03 | 9,676 | $1,683,949 | 315,407 |
| 2026-01-09 04:35 | 2026-01-06 | CORT | CORCEPT THERAPEUTICS INC | Guyer William | Officer | OPT+S | $35.18 | 20,000 | $703,656 | 1,235 |
| 2026-01-09 01:20 | 2026-01-06 | PTCT | PTC THERAPEUTICS, INC. | Gravier Pierre | Officer | SELL | $76.95 | 2,139 | $164,596 | 90,310 |
| 2026-01-09 01:20 | 2026-01-06 | PTCT | PTC THERAPEUTICS, INC. | Klein Matthew B. | Director, Officer | SELL | $77.15 | 8,165 | $629,895 | 396,967 |
| 2026-01-09 01:20 | 2026-01-06 | PTCT | PTC THERAPEUTICS, INC. | Utter Christine Marie | Officer | SELL | $77.19 | 2,616 | $201,919 | 73,727 |
| 2026-01-09 01:20 | 2026-01-06 | PTCT | PTC THERAPEUTICS, INC. | Golden Lee Scott | Officer | SELL | $77.12 | 1,982 | $152,855 | 93,294 |
| 2026-01-09 01:20 | 2026-01-06 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | Officer | OPT+S | $77.31 | 6,618 | $511,642 | 117,659 |
| 2026-01-09 01:20 | 2026-01-06 | PTCT | PTC THERAPEUTICS, INC. | Almstead Neil Gregory | Officer | SELL | $77.19 | 2,411 | $186,098 | 6,850 |
| 2026-01-09 01:20 | 2026-01-06 | PTCT | PTC THERAPEUTICS, INC. | Pauwels Eric | Officer | SELL | $77.18 | 3,141 | $242,416 | 87,489 |
| 2026-01-09 02:07 | 2026-01-07 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $40.09 | 328 | $13,149 | 38,872 |
| 2026-01-08 02:31 | 2026-01-05 | NAMS | NewAmsterdam Pharma Co N.V. | Kastelein Johannes Jacob Pieter | Director, Officer | SELL | $33.25 | 6,000 | $199,500 | 73,481 |
| 2026-01-08 02:27 | 2026-01-05 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | Officer | SELL | $33.25 | 2,647 | $88,013 | 12,353 |
| 2026-01-08 04:15 | 2026-01-05 | ANTX | AN2 Therapeutics, Inc. | Day Lucy | Officer | SELL | $1.01 | 8,807 | $8,883 | 75,363 |
| 2026-01-08 04:15 | 2026-01-05 | ANTX | AN2 Therapeutics, Inc. | Prior Stephen David | Officer | SELL | $1.01 | 6,462 | $6,507 | 59,086 |
| 2026-01-08 04:12 | 2026-01-05 | ANTX | AN2 Therapeutics, Inc. | Eizen Joshua M | Officer | SELL | $1.00 | 24,854 | $24,963 | 152,499 |
| 2026-01-08 01:27 | 2026-01-05 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Officer | SELL | $97.24 | 5,160 | $501,753 | 65,888 |
| 2026-01-08 01:26 | 2026-01-05 | NUVL | Nuvalent, Inc. | Noci Darlene | Officer | SELL | $97.25 | 7,417 | $721,320 | 40,617 |
| 2026-01-08 01:26 | 2026-01-05 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | Officer | SELL | $97.26 | 6,952 | $676,158 | 42,134 |
| 2026-01-08 01:26 | 2026-01-05 | NUVL | Nuvalent, Inc. | Turner Christopher Durant | Officer | SELL | $97.25 | 7,417 | $721,320 | 55,130 |
| 2026-01-08 01:25 | 2026-01-05 | NUVL | Nuvalent, Inc. | Balcom Alexandra | Officer | SELL | $97.25 | 7,417 | $721,320 | 81,733 |
| 2026-01-08 01:25 | 2026-01-05 | NUVL | Nuvalent, Inc. | Porter James Richard | Director, Officer | SELL | $97.26 | 27,433 | $2,668,260 | 278,629 |
| 2026-01-08 01:28 | 2026-01-05 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% owner | SELL | $6.04 | 12,918 | $78,012 | 753,562 |
| 2026-01-08 00:30 | 2026-01-06 | ALXO | Alx Oncology Holdings Inc. | Pinto Shelly | Officer | SELL | $1.11 | 3,925 | $4,357 | 88,273 |
| 2026-01-08 02:27 | 2026-01-05 | NAMS | NewAmsterdam Pharma Co N.V. | Somaiya Mayur Ian | Officer | SELL | $33.25 | 5,118 | $170,174 | 32,882 |
| 2026-01-08 01:46 | 2026-01-05 | ARQT | Arcutis Biotherapeutics Inc. | Burnett Patrick | Officer | SELL | $28.98 | 2,490 | $72,166 | 94,120 |
| 2026-01-08 01:11 | 2026-01-05 | CRNX | Crinetics Pharmaceuticals, Inc. | Kalofonos Isabel | Officer | OPT+S | $55.00 | 2,500 | $137,500 | 834 |
| 2026-01-07 21:50 | 2026-01-05 | INDV | Indivior Pharmaceuticals, Inc. | Humphreys Keith | Director | BUY | $35.39 | 775 | $27,429 | 5,802 |
| 2026-01-07 21:51 | 2026-01-05 | INDV | Indivior Pharmaceuticals, Inc. | Ryan Barbara | Director | BUY | $35.39 | 775 | $27,429 | 1,963 |
| 2026-01-07 21:47 | 2026-01-05 | INDV | Indivior Pharmaceuticals, Inc. | Wheadon David E. | Director | BUY | $35.39 | 1,771 | $62,680 | 14,395 |
| 2026-01-08 04:13 | 2026-01-05 | ANTX | AN2 Therapeutics, Inc. | Chanda Sanjay | Officer | SELL | $1.01 | 9,251 | $9,332 | 75,823 |
| 2026-01-07 21:48 | 2026-01-05 | INDV | Indivior Pharmaceuticals, Inc. | Stejbach Mark | Director | BUY | $35.39 | 775 | $27,429 | 16,847 |
| 2026-01-08 00:05 | 2026-01-05 | IRWD | IRONWOOD PHARMACEUTICALS INC | Silver Ronald | Officer | SELL | $4.60 | 35,416 | $162,914 | 276,809 |
| 2026-01-08 00:23 | 2026-01-05 | AGIO | Agios Pharmaceuticals Inc. | Milanova Tsveta | Officer | OPT+S | $27.02 | 2,872 | $77,601 | 34,793 |
| 2026-01-08 00:05 | 2026-01-05 | TVTX | Travere Therapeutics, Inc. | Inrig Jula | Officer | SELL | $39.74 | 2,476 | $98,404 | 86,311 |
| 2026-01-08 00:15 | 2026-01-05 | RCUS | Arcus Biosciences, Inc. | Jaen Juan C. | Officer | SELL | $21.41 | 31,823 | $681,343 | 922,240 |
| 2026-01-08 00:55 | 2026-01-05 | CLYM | Climb Bio, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | BUY | $3.50 | 7,111 | $24,889 | 3,403,429 |
| 2026-01-07 21:49 | 2026-01-05 | INDV | Indivior Pharmaceuticals, Inc. | NINIVAGGI DANIEL A | Director | BUY | $35.39 | 775 | $27,429 | 16,923 |
| 2026-01-07 20:45 | 2026-01-05 | ACTU | Actuate Therapeutics Inc. | THOMSON TODD S | Director, 10% owner | SELL | $5.80 | 280,000 | $1,624,000 | 904,795 |
| 2026-01-08 03:00 | 2026-01-05 | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | Director, Officer, 10% owner | OPT+S | $171.30 | 139,414 | $23,881,618 | 7,229 |
| 2026-01-08 01:12 | 2026-01-05 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $0.65 | 71,054 | $45,880 | 2,401,243 |
| 2026-01-08 00:31 | 2026-01-05 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $487.38 | 14,625 | $7,127,877 | 0 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.